The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis

Tuberculosis

Volumn 101, Issue , 2016, Pages 146-150

  Shen, Lei ^a   Shi, Hong ^a   Gao, Yan ^b   Ou, Qinfang ^c   Liu, Qianqian ^b   Liu, Yuanyuan ^b   Wu, Jing ^b   Zhang, Wenhong ^b,d   Fan, Lin ^e   Shao, Lingyun ^b  

^a SHANGHAI PULMONARY HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c Wu Xi Infectious Diseases Hospital   (China)

^d FUDAN UNIVERSITY   (China)

^e TONGJI UNIVERSITY   (China)

Author keywords

PD 1; PD L1; T cell subsets; Tuberculosis

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUBERCULOSTATIC AGENT; BIOLOGICAL MARKER; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ARTICLE; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUBERCULOSIS; BLOOD; IMMUNOLOGY; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ANTIGENS, CD274; ANTITUBERCULAR AGENTS; BIOMARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84991695795     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2016.10.001     Document Type: Article

References (26)

1. [1] Zumla, A., et al. The WHO 2014 Global tuberculosis report-further to go. Lancet Global Health, 3(1), 2015 E10-E12.
2. [2] Ishida, Y., et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:11 (1992), 3887–3895.
3. [3] Keir, M.E., Francisco, L.M., Sharpe, A.H., PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 19:3 (2007), 309–314.
4. [4] Francisco, L.M., Sage, P.T., Sharpe, A.H., The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236 (2010), 219–242.
5. [5] Fife, B.T., Pauken, K.E., The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N. Y Acad Sci 1217 (2011), 45–59.
6. [6] Freeman, G.J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:7 (2000), 1027–1034.
7. [7] Barber, D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:7077 (2006), 682–687.
8. [8] Trautmann, L., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12:10 (2006), 1198–1202.
9. [9] Boni, C., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81:8 (2007), 4215–4225.
10. [10] Barber, D.L., et al. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol 186:3 (2011), 1598–1607.
11. [11] Lazar-Molnar, E., et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U. S. A 107:30 (2010), 13402–13407.
12. [12] Abbas, A.K., et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 14:4 (2013), 307–308.
13. [13] Boer, M.C., Joosten, S.A., Ottenhoff, T.H., Regulatory t-cells at the interface between human host and pathogens in infectious diseases and vaccination. Front Immunol, 6, 2015, 217.
14. [14] Shen, T., et al. Characteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients. Virol J, 8, 2011, 279.
15. [15] Trinath, J., et al. Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells. J Infect Dis 205:4 (2012), 694–696.
16. [16] Tousif, S., et al. T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS One, 6(5), 2011, e19864.
17. [17] Jurado, J.O., et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 181:1 (2008), 116–125.
18. [18] Alvarez, I.B., et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis 202:4 (2010), 524–532.
19. [19] Singh, A., et al. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 208:4 (2013), 603–615.
20. [20] Hassan, S.S., et al. PD-1, pd-l1 and pd-l2 gene expression on t-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS One, 10(9), 2015, e0137646.
21. [21] Yin, W., et al. PD-1/PD-Ls pathways between CD4(+) T cells and pleural mesothelial cells in human tuberculous pleurisy. Tuberculosis (Edinb) 94:2 (2014), 131–139.
22. [22] Hougardy, J.M., et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 176:4 (2007), 409–416.
23. [23] Feruglio, S.L., et al. Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection. Clin Exp Immunol 179:3 (2015), 454–465.
24. [24] Francisco, L.M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:13 (2009), 3015–3029.
25. [25] Franceschini, D., et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 119:3 (2009), 551–564.
26. [26] Periasamy, S., et al. Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation with Mycobacterium tuberculosis. J Infect Dis 203:9 (2011), 1256–1263.